Professional development

When biomarkers aren't an option in vaccine research, we need a well-supported alternative

NIDA has launched a $100,000 competition to encourage startup companies

Sitting Down With… Robert A. Weinberg, founding member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology, USA.

When it comes to industry–academia partnerships, it’s quality – not quantity – that counts.

From being one of the first clinicians to voice doubts over Vioxx, to his latest book calling for a complete transformation of the patient–doctor relationship, Eric Topol has never been afraid to raise his head above the parapet.

Sitting Down With… Thomas Mellman, Professor and Director, Center for Clinical and Translational Research and Stress/Sleep Studies Program, Howard University College of Medicine, Washington, DC, USA.

The pharmaceutical industry receives its fair share of both praise and scorn. Behind the politics, the hard work and impressive achievements of legions of industry researchers often go unnoticed.

Sitting Down With…John Doench, Associate Director, Genetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.

There is an assumption that doctors and business don’t mix. But I believe physicians are ideally placed to bring new clinical innovations from a bright idea to a brand new product.

Open innovation is more than just the latest pharma industry buzzword. Done right, it can help overcome funding challenges and accelerate discovery across the board.